Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

被引：13

作者：

Smit, E. F. ^{[1
]}

Felip, E. ^{[2
,3
]}

Uprety, D. ^{[4
]}

Nakagawa, K. ^{[5
]}

Paz-Ares, L. ^{[6
]}

Pacheco, J. ^{[7
,8
]}

Li, B. T. ^{[9
]}

Planchard, D. ^{[10
]}

Baik, C. ^{[11
]}

Goto, Y. ^{[12
]}

Murakami, H. ^{[13
]}

Saltos, A. ^{[14
]}

Saxena, K. ^{[15
]}

Shiga, R. ^{[16
]}

Cheng, Y. ^{[17
]}

Yan, Q. ^{[18
]}

Feng, W. ^{[19
]}

Janne, P. A. ^{[20
,21
]}

机构：

[1] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[2] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[3] Vall Hebron Inst Oncol, Barcelona, Spain

[4] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA

[5] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[6] Univ Navarra, Dept Med Oncol, Univ Navarra Clin, Navarra, Spain

[7] Univ Colorado Anschutz, Internal Med, Aurora, CO USA

[8] Univ Colorado Anschutz, Div Med Oncol, Aurora, CO USA

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Gustave Roussy, Med Oncol, Thorac Team, Villejuif, France

[11] Univ Washington, Thorac Head & Neck Med Oncol, Seattle, WA USA

[12] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[14] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[15] Daiichi Sankyo Inc, R&D, Basking Ridge, NJ USA

[16] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[17] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Global Compan Diagnost, Basking Ridge, NJ USA

[20] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[21] Belfer Ctr Appl Canc Sci, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

975P

引用

页码：S994 / S995

页数：2